Surmodics reports positive one-year data for SurVeil drug-coated balloon

This article was originally published here

SurmodicsSurmodics (NSDQ:SRDX) touted data this week from an early feasibility study of the company’s SurVeil drug-coated balloon in patients with symptomatic peripheral artery disease due to de novo lesions of the femoral and popliteal arteries.

All of the study’s 13 subjects met the acute success measures of safety at 12 months, Surmodics reported, and no participants required re-intervention of either the target lesion or the target vessel.

Get the full story at our sister site, Drug Delivery Business News.

The post Surmodics reports positive one-year data for SurVeil drug-coated balloon appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply